581 7. Oltre il Trapianto Bibliografia [1] Callahan C, Barry A, Fooks-Parker S, Smith L, Baniewicz D, Hobbie W. Pediatric Survivorship: Considerations following CAR T-cell therapy. Clin J Oncol Nurs, 2019 23: 35–41. doi: 10.1188/19.CJON. S1.35-41 [2] Del Bufalo F, Merli P, Alessi I, Locatelli F. B-cell depleting immunotherapies: therapeutic opportunities and toxicities. Expert Rev Clin Immunol, 2019 15: 497–509. doi: 10.1080/1744666X.2019.1573672 [3] Finch EA, Duke E, Hwang EI, Packer RJ. Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. Pediatr Neurol, 2020 107: 7–15. doi: 10.1016/j.pediatrneurol.2020.01.004 [4] Kenyon M, Murray J, Ellard R, Hutt D. Education Needs for Nurses in Adult and Paediatric Units [Internet], in Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (eds): The EBMT/EHA CAR-T Cell Handbook. Cham, Springer International Publishing, 2022 207–213. [5] Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol Off J Eur Soc Med Oncol, 2022 33: 259–275. doi: 10.1016/j.annonc.2021.12.003 [6] Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O’Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol, 2019 16: 45–63. doi: 10.1038/s41571-018-0075-2 [7] Beaupierre A, Kahle N, Lundberg R, Patterson A. Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy. J Adv Pract Oncol, 2019 10: 29–40. doi: 10.6004/jadpro.2019.10.4.12 [8] Das RK, O’Connor RS, Grupp SA, Barrett DM. Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Adv, 2020 4: 4653–4664. doi: 10.1182/bloodadvances.2020001797 [9] Browne EK, Daut E, Hente M, Turner K, Waters K, Duffy EA. Evidence-Based Recommendations for Nurse Monitoring and Management of Immunotherapy-Induced Cytokine Release Syndrome: A Systematic Review from the Children’s Oncology Group. J Pediatr Oncol Nurs, 2021 38: 399–409. [10] Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol, 2018 53: 164–181. doi: 10.1016/j.copbio.2018.01.025 [11] Buitrago J, Adkins S, Hawkins M, Iyamu K, Oort T. Adult Survivorship: Considerations Following CAR T-Cell Therapy. Clin J Oncol Nurs, 2019 23: 42–48. doi: 10.1188/19.CJON.S1.42-48 [12] Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, 2019 25: 625–638. doi: 10.1016/j.bbmt.2018.12.758 [13] Reiser V. Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications. J Adv Pract Oncol, 2020 11: 159–167. doi: 10.6004/jadpro.2020.11.2.4 [14] Anderson K, Latchford T. Associated Toxicities: Assessment and Management Related to CAR T-Cell Therapy. Clin J Oncol Nurs , 2019 23: 13–19. doi: 10.1188/19.CJON.S1.13-19 [15] Baer B, Dudley CV, Simons RM. Management Principles Associated With Cytokine Release Syndrome. Semin Oncol Nurs, 2019 35: 150931. doi: 10.1016/j.soncn.2019.08.010. [16] Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel H-G, Sadelain M, Brentjens RJ. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov, 2018 8: 958–971. doi: 10.1158/2159-8290.CD-17-1319 [17] Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol OncolJ Hematol Oncol, 2018 11: 35. doi: 10.1186/s13045-018-0571-y [18] Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol, 2019 15: 813–822. doi: 10.1080/1744666X.2019.1629904 [19] Ganatra S, Carver JR, Hayek SS, Ky B, Leja MJ, Lenihan DJ, Lenneman C, Mousavi N, Park JH, Perales MA, Ryan TD, Scherrer-Crosbie M, Steingart RM, Yang EH, Zaha V, Barac A, Liu JE. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. J Am Coll Cardiol, 2019 74: 3153–3163. doi: 10.1016/j.jacc.2019.10.049 [20] Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020 105: 297–316. doi: 10.3324/haematol.2019.229781 [21] Shalabi H, Sachdev V, Kulshreshtha A, Cohen JW, Yates B, Rosing DR, Sidenko S, Delbrook C, Mackall C, Wiley B, Lee DW, Shah NN. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer, 2020 8: e001159. doi: 10.1136/jitc-2020-001159 [22] Hill JA, Giralt S, Torgerson TR, Lazarus HM. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev , 2019 38: 100596. doi: 10.1016/j.blre.2019.100596 [23] Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, Díaz de Heredia C, Fortuny-Guasch C, García-Cadenas I, García-Vidal C, González-Vicent M, Hernani R, Kwon M, Machado M, Martínez-Gómez X, Maldonado VO, Pla CP, Pi ana JL, Pomar V, Reguera-Ortega JL, Salavert M, Soler-Palacín P, Vázquez-López L, Barba P, Ruiz-Camps I. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection, 2021 49: 215–231. doi: 10.1007/s15010-020-01521-5 [24] Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Laetsch TW, Wiener L, Gardner RA, Nussenblatt V, Hill JA, Curran KJ, Olson TS, Annesley C, Wang H-W, Khan J, Pasquini MC, Duncan CN, Grupp SA, Pulsipher MA, Shah NN. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol, 2021 18: 363–378. doi: 10.1038/s41571-020-00456-y [25] Taylor L, Rodriguez ES, Reese A, Anderson K. Building a Program: Implications for Infrastructure, Nursing Education, and Training for CAR T-Cell Therapy. Clin J Oncol Nurs, 2019 23: 20–26. doi: 10.1188/19.CJON.S1.20-26 [26] Beaupierre A. Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-Cell Therapy in Multiple Care Settings. Number 2 April 2019, 1969 23: 27–34. doi:10.6004/jadpro.2019.10.4.12
RkJQdWJsaXNoZXIy ODUzNzk5